ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 139 filers reported holding ARRAY BIOPHARMA INC in Q4 2013. The put-call ratio across all filers is 3.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $26,815,000 | -7.3% | 578,782 | -51.2% | 0.09% | -4.3% |
| Q1 2019 | $28,925,000 | +329.6% | 1,186,439 | +187.6% | 0.09% | +327.3% |
| Q1 2018 | $6,733,000 | -50.8% | 412,582 | -61.4% | 0.02% | -51.1% |
| Q4 2017 | $13,695,000 | -49.7% | 1,069,937 | -51.7% | 0.04% | -53.6% |
| Q3 2017 | $27,229,000 | +459.9% | 2,213,718 | +281.0% | 0.10% | +438.9% |
| Q2 2017 | $4,863,000 | -76.2% | 581,009 | -74.5% | 0.02% | -73.9% |
| Q1 2017 | $20,406,000 | +571.5% | 2,282,600 | +407.0% | 0.07% | +527.3% |
| Q3 2016 | $3,039,000 | +250.1% | 450,229 | +118.9% | 0.01% | +175.0% |
| Q4 2015 | $868,000 | +57.0% | 205,654 | +69.5% | 0.00% | +33.3% |
| Q3 2015 | $553,000 | -92.4% | 121,357 | -88.0% | 0.00% | -91.2% |
| Q2 2015 | $7,284,000 | +21.3% | 1,010,275 | +24.0% | 0.03% | +13.3% |
| Q1 2015 | $6,006,000 | +250.6% | 814,863 | +125.0% | 0.03% | +233.3% |
| Q4 2014 | $1,713,000 | +82.4% | 362,119 | +93.2% | 0.01% | +80.0% |
| Q4 2013 | $939,000 | – | 187,453 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 9,169,276 | $66,110,000 | 11.67% |
| Redmile Group, LLC | 13,623,620 | $98,226,000 | 8.05% |
| First Light Asset Management, LLC | 849,374 | $6,124,000 | 2.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 9,529,361 | $68,707,000 | 2.29% |
| Opus Point Partners Management, LLC | 320,000 | $2,307,000 | 1.83% |
| KOPP INVESTMENT ADVISORS LLC | 383,022 | $2,762,000 | 1.23% |
| Artal Group S.A. | 3,710,000 | $26,749,000 | 1.15% |
| EcoR1 Capital, LLC | 400,000 | $2,884,000 | 0.96% |
| Cormorant Asset Management, LP | 850,000 | $6,129,000 | 0.82% |
| SPHERA FUNDS MANAGEMENT LTD. | 800,000 | $5,768,000 | 0.56% |